Oncozenge AB (ST:ONCOZ) — Market Cap & Net Worth
Market Cap & Net Worth: Oncozenge AB (ONCOZ)
Oncozenge AB (ST:ONCOZ) has a market capitalization of $5.29 Million (Skr49.17 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #28559 globally and #637 in its home market, demonstrating a 1.16% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oncozenge AB's stock price Skr3.50 by its total outstanding shares 14048068 (14.05 Million). Also see balance sheet size of Oncozenge AB for a full breakdown of the balance sheet.
Oncozenge AB Market Cap History: 2021 to 2026
Oncozenge AB's market capitalization history from 2021 to 2026. Data shows change from $17.48 Million to $5.29 Million (-20.03% CAGR). Also see Oncozenge AB cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Oncozenge AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.23 Billion | 0.03% | #192 of 281 |
Weight: Oncozenge AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Oncozenge AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oncozenge AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Oncozenge AB for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.84x
Oncozenge AB's market cap is 3.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $4.67 Million | $3.00K | -$15.90 Million | 1557.15x | N/A |
| 2024 | $5.67 Million | $1.00K | -$8.69 Million | 5669.24x | N/A |
| 2025 | $10.22 Million | $2.66 Million | -$15.94 Million | 3.84x | N/A |
Competitor Companies of ONCOZ by Market Capitalization
Companies near Oncozenge AB in the global market cap rankings as of September 19, 2026. Review Oncozenge AB tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Oncozenge AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Oncozenge AB Historical Marketcap From 2021 to 2026
Between 2021 and today, Oncozenge AB's market cap moved from $17.48 Million to $ 5.29 Million, with a yearly change of -20.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr5.29 Million | -48.22% |
| 2025 | Skr10.22 Million | +80.27% |
| 2024 | Skr5.67 Million | +21.36% |
| 2023 | Skr4.67 Million | -43.82% |
| 2022 | Skr8.31 Million | -52.42% |
| 2021 | Skr17.48 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Oncozenge AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.29 Million USD |
| MoneyControl | $5.29 Million USD |
| MarketWatch | $5.29 Million USD |
| marketcap.company | $5.29 Million USD |
| Reuters | $5.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oncozenge AB
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.